Qualità di vita

Aperti

Titolo Codice Patologia Fase Clinicaltrials.gov EudraCT
Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. A prospective evlaution of quality of life outcomes AML1310 AML

A Survivorship Project to understAnd and to impRove long-Term outcomes for Acute myeloid leukemia patients (SPARTA): The SPARTA platform.

GIMEMA-EORTC 1621-QLG-LG (SPARTA) AML
Long Term Quality of Life Symptom Burden in Acute Promyelocytic Leukemia (APL) Patients Treated with Arsenic Trioxide (ATO) or Standard Chemotherapy  QoL-APL0816 APL
A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patient with newLy diagnosed, high-risk acute prOmyelocytic leukemia: A Prospective Evaluation of Quality of Life Outcomes QoL-APOLLO Trial APL
The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase: a phase IIIb, multicenter study to assess the complete molecular response. A Prospective evaluation of Quality of Life Outcomes CML0811 CML

“An international field study for the reliability and validity of the Phase IV EORTC Quality of Life module for patients with Chronic Myeloid Leukemia (EORTC QLQ-CML24)”

 GIMEMA/EORTC- QoLCML0916 CML

BOSUTINIB EFFICACY SAFETY TOLERABILITY (BEST) STUDY IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS FAILING FRONT-LINE TREATMENT WITH OTHER TYROSINE KINASE INHIBITORS: A Prospective evaluation of Quality of Life Outcomes 
CML1516) 

 QoL-BEST CML
Mid to Long-term Quality of Life Effects Of imatiNIb versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS) QoL-CML0713 (LEONIDAS) CML
Front-line treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) with dasatinib. An observational multicentric study. A Prospective evaluation of Quality of Life Outcomes QoL-CML1113 CML
Optimizing Ponatinib USe (OPUS). A GIMEMA phase 2 study of the activity and risk profile of ponatinib, 30 mg once daily, in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) patients resistant to imatinib: AProspective evaluation of Quality of Life Outocmes QoL-OPUS CML
Patient Reported Outcome Measurements Over Time In ONcology (PROMOTION) Project GIMEMA/EORTC QLG PROMOTION Project GIMEMA / EORTC QLG PROMOTION Project http://promotionproject.gimema.it/
Electronic data collection to improve quality of care in home-care treated patients PROJECT GIMEMA/ASDOM (ROMAIL) GIMEMA/ASDOM
Prognostic significance and longitudinal assessment ofPatient-Reported Outcomes in MYelodysplastic Syndromes (PROMYS):PROMYS International Registry PROMYS MDS
CLinical decision-making, prognosis, quAlity of life and satisfaction with caRe in patIents with relapsed/refracTory multiple mYeloma (CLARITY).  MM1016 MM

Qualità di vita

Chiusi

Titolo Codice Patologia Fase Clinicaltrials.gov EudraCT
A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regi-men) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL0406): Investigating long-term quality of life outcomes

 APL0406 APL

Long-term quality of Life and late complications in survivors of Acute Promyelocytic Leukemia (APL) treated with ATRA and standard chemotherapy. Long-term follow-up of patients treated in the GIMEMA AIDA 0493 and AIDA 2000

 QoL-APL0512 APL

Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response Treated with Imatinib as First Line Therapy: Health-Related Quality of Life, Symptom Burden and Adherence to Therapy Issues.

 GIMEMA QoL-CML0208 CML

Patient Reported Outcomes in Chronic Myeloid Leukemia

 GIMEMA/EORTC QoL - CML0310 CML
 Health-related Quality of Life and Fatigue in adult patients with primary Immune Thrombocytopenic Purpura (pITP). GIMEMA QoL-ITP0411 ITP

Validation of a Myelodysplasia-Specific Measure of Quality of Life

 MDS0613 (QUALMS) MDS

Il GIMEMA ha creato nel 2007 la Health Outcomes Research Unit, con lo scopo di sviluppare e gestire programmi di ricerca clinica tesi a migliorare la qualità di vita dei pazienti con patologie ematologiche e, in generale, a contribuire a migliorare sempre più la qualità dell’assistenza sanitaria.
Lo scopo di uno studio che abbia tra i suoi obiettivi anche la valutazione della qualità di vita del paziente è quello di fornire dati scientifici, basati sull’evidenza, utili ai medici e ai pazienti stessi per compiere scelte terapeutiche sempre più consapevoli.
Questa Unità sta portando avanti una serie di importanti programmi di ricerca a livello nazionale ed internazionale in diverse patologie ematologiche quali leucemie acute, croniche e mielodisplasie. Molti degli studi attualmente in corso sono condotti in collaborazione con l’Associazione Italiana contro le Leucemie Linfomi e Mieloma AIL e con importanti Enti di ricerca in Europa e negli USA.

PROMOTION Registry

PROMYS International Registry